يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Marcin Krzystanek"', وقت الاستعلام: 0.94s تنقيح النتائج
  1. 1

    المصدر: Biswas, D, Birkbak, N J, Rosenthal, R, Hiley, C T, Lim, E L, Papp, K, Boeing, S, Krzystanek, M, Djureinovic, D, La Fleur, L, Greco, M, Döme, B, Fillinger, J, Brunnström, H, Wu, Y, Moore, D A, Skrzypski, M, Abbosh, C, Litchfield, K, Al Bakir, M, Watkins, T B K, Veeriah, S, Wilson, G A, Jamal-Hanjani, M, Moldvay, J, Botling, J, Chinnaiyan, A M, Micke, P, Hackshaw, A, Bartek, J, Csabai, I, Szallasi, Z, Herrero, J, McGranahan, N, Swanton, C & TRACERx Consortium 2019, ' A clonal expression biomarker associates with lung cancer mortality ', Nature Medicine, vol. 25, no. 10, pp. 1540-1548 . https://doi.org/10.1038/s41591-019-0595-z

  2. 2
  3. 3
  4. 4
  5. 5

    المصدر: Szikriszt, B, Poti, A, Pipek, O, Krzystanek, M, Kanu, N, Molnar, J, Ribli, D, Szeltner, Z, Tusnady, G E, Csabai, I, Szallasi, Z I, Swanton, C & Szuts, D 2016, ' A comprehensive survey of the mutagenic impact of common cancer cytotoxics ', Genome Biology, vol. 17, 99 . https://doi.org/10.1186/s13059-016-0963-7
    Genome Biology

    وصف الملف: application/pdf

  6. 6

    المصدر: Marquard, A M, Eklund, A C, Joshi, T, Krzystanek, M, Favero, F, Wang, Z C, Richardson, A L, Silver, D P, Szallasi, Z I & Birkbak, N J 2015, ' Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs ', Biomarker Research, vol. 3, no. 9 . https://doi.org/10.1186/s40364-015-0033-4
    Biomarker Research

    وصف الملف: application/pdf

  7. 7
  8. 8

    المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical oncology, CCA - Innovative therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

    المصدر: Cancer Immunology Immunotherapy, 63(5), 449-458. SPRINGER
    Cancer Immunology, Immunotherapy, 63(5), 449-458
    Cancer Immunology, Immunotherapy
    Kelderman, S, Heemskerk, B, van Tinteren, H, van den Brom, R R H, Hospers, G A P, van den Eertwegh, A J M, Kapiteijn, E W, de Groot, J W B, Soetekouw, P, Jansen, R L, Fiets, E, Furness, A J S, Renn, A, Krzystanek, M, Szallasi, Z, Lorigan, P, Gore, M E, Schumacher, T N M, Haanen, J B A G, Larkin, J M G & Blank, C U 2014, ' Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma ', Cancer Immunology and Immunotherapy, vol. 63, no. 5, pp. 449-458 . https://doi.org/10.1007/s00262-014-1528-9
    Cancer Immunology and Immunotherapy, 63(5), 449-458. Springer Science and Business Media Deutschland GmbH
    Cancer Immunology Immunotherapy, 63(5), 449-458. Springer

  9. 9